(2025) Discrepancy between mammographic and pathological sizing of screen-detected DCIS: risk factors and impact on ipsilateral recurrence rates. European Journal of Surgical Oncology, 51 (11), [110431]. (doi:10.1016/j.ejso.2025.110431).
Abstract
Background: Discrepancy between mammographic and pathological sizing of DCIS can lead to surgical overtreatment, with poorer cosmesis or unnecessary mastectomy, or undertreatment and recurrence. Methods: Within the UK Sloane Project prospective cohort study of screen-detected DCIS (2003–2012), we investigated factors associated with 'pathology larger (PL)’ (pathological larger than mammographic size) or ‘mammogram larger (ML)’ (mammographic larger than pathologic size), size discrepancy and the impact on ipsilateral recurrence. Results: Among 9937 patients (mean age 60; range 46–87), mammographic size remained constant at median 19 mm (IQR 10–35)mm whilst pathological size increased from 16(10–28)mm to 20(10–33)mm (p = 0.001)over the study. The mammographic and pathological size discrepancy decreased from 3.4 mm to 0.2 mm (p < 0.05). In patients undergoing BCS, size discrepancy of ≥5 mm was associated with increased 5-year ipsilateral recurrence if lesions were PL (odds ratio(OR) 1.37 (C.I. 1.03–1.82, p = 0.03) and if lesions were ML (OR 1.4 (C.I. 1.10–1.86, p = 0.008), compared to <5 mm discrepancy. Factors associated with PL by ≥ 5 mm were high grade (OR 1.9 [95 % CI 1.5–2.4, p < 0.001]) and mastectomy (OR 4.4 [C.I. 3.8–5.1, p < 0.001]) and for ML ≥ 5 mm was larger mammographic tumour size (>40 mm; OR 115.7 [C.I. 82.3–162.6], p < 0.001]). Conclusion: Mammographic-pathological size discrepancy is associated with higher recurrence following BCS for DCIS.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.